Overview and Scope
Radiopharmaceutical theranostics refers to a combined approach in medicine that combines therapeutics (treatment) and diagnostics (diagnosis) using radiopharmaceuticals. These are used for patient diagnosis, therapy, and personalized management.
Sizing and Forecast
The radiopharmaceutical theranostics market size has grown rapidly in recent years. It will grow from $2.51 billion in 2023 to $2.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to radiopharmaceutical development, clinical research advances, investment in research, regulatory approval, nuclear medicine progress.
The radiopharmaceutical theranostics market size is expected to see rapid growth in the next few years. It will grow to $4.9 billion in 2028 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to biomarker discovery and validation, genomic and proteomic technologies, precision radiotherapy development, interdisciplinary collaborations, patient advocacy and support. Major trends in the forecast period include ethical and legal considerations, telemedicine in theranostics,patient-centric care, radiopharmaceutical customization, nano-theranostics development.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-theranostics-global-market-report
Segmentation & Regional Insights
The radiopharmaceutical theranostics market covered in this report is segmented –
1) By Product Type: Alpha Emitters, Beta Emitters, Positron Emission Tomography (PET) Tracers
2) By Source: Nuclear Reactors, Cyclotrons
3) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioscopes
4) By Indication: Oncology, Cardiology, Neurology, Other Indications
5) By End User: Hospitals, Diagnostic Imaging Centers, Academic And Research Institutes, Other End Users
North America was the largest region in the radiopharmaceutical theranostics market in 2023. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=11951&type=smp
Major Driver Impacting Market Growth
The rising incidence of cancer is expected to propel the growth of the radiopharmaceutical theranostics market going forward. Cancer refers to a disease or condition of complex and abnormal growth of cells that can invade and spread to other parts of the body. Radiopharmaceutical theranostics helps in cancer treatment by providing targeted and personalized approaches. For instance, in 2023, according to the American Cancer Society, a US-based voluntary cancer health organization, in the US, 1.9 million new cancer cases are estimated to be diagnosed and about 609,820 deaths may occur due to cancer. Further, 88% of the people diagnosed are expected to belong to the 50 years or above age group. Therefore, the rising incidence of cancer is driving the growth of the radiopharmaceutical theranostics market.
Key Industry Players
Major companies operating in the radiopharmaceutical theranostics market report are Cardinal Health Inc., AstraZeneca PLC, GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc., RayzeBio Inc., Fusion Pharmaceuticals Inc., Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd., Ratio Therapeutics Inc., Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.
The radiopharmaceutical theranostics market report table of contents includes:
1. Executive Summary
2. Radiopharmaceutical Theranostics Market Characteristics
3. Radiopharmaceutical Theranostics Market Trends And Strategies
4. Radiopharmaceutical Theranostics Market – Macro Economic Scenario
5. Global Radiopharmaceutical Theranostics Market Size and Growth
.
.
.
31. Radiopharmaceutical Theranostics Market Other Major And Innovative Companies
32. Global Radiopharmaceutical Theranostics Market Competitive Benchmarking
33. Global Radiopharmaceutical Theranostics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Radiopharmaceutical Theranostics Market
35. Radiopharmaceutical Theranostics Market Future Outlook and Potential Analysis
36.Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
